The Paradigm share price is rocketing 22% today. Here’s why

Osteoarthritis affects approximately 16% of the population in the developed world.

| More on:
Group of Imugene scientists cheering in the lab after the company received another patent for HER-Vaxx

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • The Paradigm share price is soaring today
  • The ASX healthcare share received Fast Track Designation from the US FDA
  • More than 72 million people in the US, EU, Canada, and Australia suffer from osteoarthritis

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price is rocketing today, up 21.55% in early afternoon trading.

Paradigm shares closed yesterday at $1.16 and are currently trading for $1.41. However, they climbed as high as $1.60 earlier in the day — a 38% gain on yesterday’s close.

The drug development company is focused on developing and commercialising Pentosan Polysulfate Sodium (PPS) to treat pain associated with a range of musculoskeletal disorders.

Below we look at this morning’s announcement that’s seeing the Paradigm share price surge.

What clinical trial news was announced?

Paradigm’s share price is rocketing after the company reported that the US Food and Drug Administration (FDA) has granted Fast Track Designation for its phase 3 program testing the efficacy of PPS, trademarked Zilosul, to treat osteoarthritis (OA).

OA affects some 16% of the population in the developed world, with more than 72 million people in the US, EU, Canada, and Australia suffering from the affliction.

Paradigm said the FDA’s Fast Track program would help expedite its phase 3 program, providing the company with greater opportunities to interact and collaborate with the FDA.

It added that the Fast Track designation indicates the FDA acknowledges that preliminary data indicates Zilosul has the potential to address the unmet medical needs of people suffering from OA.

Commenting on the FDA’s decision, Paradigm’s interim CEO Donna Skerrett said:

This is welcome news from the US FDA as the company continues to gain momentum in site activation and participant screening across the 56 selected sites in the US. Given the need to improve therapeutic options for patients suffering from pain and loss of functionality associated with OA, we are excited to have this Fast Track Designation granted for Zilosul and the regulatory support it provides in expediting the phase 3 development program to advance this promising treatment to patients sooner.

Paradigm share price snapshot

Despite the big intraday boost today, the Paradigm share price remains down 27% so far this year. That compares to a year-to-date loss of 3% posted by the All Ordinaries Index (ASX: XAO).

The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Two researchers discussing results of a study with each other.
Healthcare Shares

Here’s how ASX 200 healthcare shares performed in June

Healthcare shares were a tad ill in June.

Read more »

A doctor appears shocked as he looks through binoculars on a blue background.
Healthcare Shares

What’s the outlook for the CSL share price in July?

We take a look at what the experts are saying about the biotech company's shares.

Read more »

Photo of a group of scientists cheering while working in a lab as the Race Oncology share price skyrockets today on positive study results
Healthcare Shares

Why is the Race Oncology share price soaring 13% today?

New trial results have excited ASX investors.

Read more »

Rising arrow on a blue graph symbolising a rising share price.
Healthcare Shares

Starphama share price lunges 5% on product relaunch

Early support for Starphama on Thursday has it off to a great start.

Read more »

Man with rocket wings which have flames coming out of them.
Healthcare Shares

Why is the Paradigm share price rocketing 20% higher today?

The Paradigm share price is having a very strong day...

Read more »

A businessman presents a company annual report in front of a group seated at a table
Healthcare Shares

Own Immutep shares? Here are 3 takeaways from the company’s investor update

Investors were mute to the update.

Read more »

A health professional wearing a stethoscope and scrubs shrugs with uncertainty.
Healthcare Shares

Has CSL been growing its dividend?

Is the biotech giant still increasing its dividends in a post-COVID world?

Read more »

Man pointing an upward line on a bar graph symbolising a rising share price.
Healthcare Shares

Why is the 4DMedical share price exploding 40% today?

4DMedical signed a three-year, nationwide contract with I-MED Radiology Network.

Read more »